Skip to main content
SpringerLink
Log in

Anxiolytika

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

  • 8084 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Anxiolytika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Außerdem werden Substanzen besprochen, deren primäre Indikation außerhalb der Angststörungen liegt, die aber auch bei diesen wirksam sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Baandrup L, Ebdrup BH, Rasmussen JØ et al (2018) Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 3:CD011481

    Article  PubMed  PubMed Central  Google Scholar 

  • Bandelow B, Sagebiel A, Belz M et al (2018) Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Brit J Psychiatry 212:333–338

    Article  Google Scholar 

  • Bedse G, Bluett RJ, Patrick TA et al (2018) Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry 8(1):92

    Article  Google Scholar 

  • Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27:1185–1215

    Article  CAS  Google Scholar 

  • Buoli M, Grassi S, Serati M et al (2017) Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother 18(13):1373–1379

    Article  CAS  Google Scholar 

  • Bürgy M (2017) Die wahnhafte Depression. Nervenarzt 88:529–537

    Article  Google Scholar 

  • Buth S, Holzbach R, Martens MS et al (2019) Problematic medication with benzodiazepines, „Z-drugs“, and opioid analgesics – an analysis of national health insurance prescription data from 2006–2016. Dtsch Arztebl Int 116:607–614

    PubMed  PubMed Central  Google Scholar 

  • Caniff K, Telega E, Bostwick JR, Gardner KN (2018) Pregabalin as adjunctive therapy in benzodiazepine discontinuation. Am J Health Syst Pharm 75:67–71

    Article  CAS  Google Scholar 

  • Chen TY, Winkelman JW, Mao WC et al (2018) The use of benzodiazepine receptor agonists and the risk of hospitalization for pneumonia: a nationwide population-based nested case-control study. Chest 153(1):161–171

    Article  Google Scholar 

  • Fluyau D, Revadigar N, Manobianco BE (2018) Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 8(5):147–168

    Article  CAS  Google Scholar 

  • Fond G, Berna F, Boyer L et al (2018) Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci 268(1):17–26

    Article  Google Scholar 

  • Gahr M, Hiemke C, Connemann BJ (2017) Update Opipramol. Fortschr Neurol Psychiatr 85:139–145

    Article  Google Scholar 

  • Gottschalk MG, Domschke K (2018) Oxytocin and anxiety disorders. Curr Top Behav Neurosci 35:467–498

    Article  CAS  Google Scholar 

  • Hata T, Kanazawa T, Hamada T et al (2018) What can predict and prevent the long-term use of benzodiazepines? J Psychiatr Res 97:94–100

    Article  Google Scholar 

  • Klass A, Glaubitz B, Tegenthoff M et al (2017) D-Cycloserine facilitates extinction learning and enhances extinction-related brain activation. Neurobiol Learn Memory 144:235–247

    Article  CAS  Google Scholar 

  • Lüddens H (2012) Anxiolytika und Hypnotika. In: Gründer G, Benkert O (Hrsg) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin Heidelberg New York, S 695–712

    Chapter  Google Scholar 

  • Mataix-Cols D, Fernández de la Cruz L, Monzani B et al (2017) D-Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry 74(5):501–510

    Article  Google Scholar 

  • Molero Y, Larsson H, D’Onofrio BM et al (2019) Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ 365:l2147

    Article  Google Scholar 

  • Murphy CP, Singewald N (2019) Role of microRNAs in anxiety and anxiety-related disorders. Curr Top Behav Neurosci 42:185–219

    CAS  PubMed  Google Scholar 

  • Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A (2017) The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep 19:103

    Article  Google Scholar 

  • Sanchez-Vidana DI, Po KK, Fung TK et al (2019) Lavender essential oil ameliorates depression-like behavior and increases neurogenesis and dendritic complexity in rats. Neurosci Lett 701:182–190

    Article  Google Scholar 

  • Schjerning O, Damkier P, Lykkegaard SE et al (2017) Pregabalin for anxiety in patients with schizophrenia – a randomized, double-blind placebo-controlled study. Schizophr Res 195:260–266

    Article  Google Scholar 

  • Slee A, Nazareth I, Bondaronek P, Liu Y et al (2019) Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 393(10173):768–777

    Article  CAS  Google Scholar 

  • Soyka M (2017) Treatment of benzodiazepine dependence. N Eng J Med 376:1147–1157

    Article  CAS  Google Scholar 

  • Stubbs B, Vancampfort D, Rosenbaum S et al (2017) An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: a metaanalysis. Psychiatry Res 249:102–108

    Article  Google Scholar 

  • Wolter DK (2017) Benzodiazepine absetzen im Alter. Wann und, wenn ja, wie? Z Gerontol Geriatr 50:115–122

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Berlin, Deutschland

    Prof. Dr. med. Ion-George Anghelescu

  2. Mainz, Deutschland

    Otto Benkert

Authors
  1. Prof. Dr. med. Ion-George Anghelescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Germany

    Otto Benkert

  2. Klinik für Psychiatrie und Psychotherapie, ehemals Universitäts-Klinikum München Campus Innenstadt, München, Germany

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anghelescu, IG., Benkert, O. (2021). Anxiolytika. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61753-3_4

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61752-6

  • Online ISBN: 978-3-662-61753-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation